In 2025, the company reported a -1.92% YoY revenue decline, reflecting portfolio shifts: Eliquis ($7.9B) remains a key anticoagulant franchise with steady demand, Prevnar family ($6.4B) continues to anchor its vaccines business despite some normalization, and Vyndaqel family ($6.38B) is rapidly growing in rare cardiomyopathy helping offset declines in other segments
One common question is about the safety and efficacy of these injections
British clinicians typically prescribe alternative ADHD medications such as methylphenidate (Ritalin, Concerta XL), lisdexamfetamine (Elvanse), or atomoxetine (Strattera)
References Akhtar TA, Orsomando G, Mehrshahi P, Lara-Nez A, Bennett MJ, Gregory JF III, Hanson AD